Home    Back

299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2009-009869-34-SE
(EUCTR)		12/10/200929/07/2009Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939 Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)
MedDRA version: 9.1;Level: LLT;Classification code 10006445;Term: Bronchiectasis
MedDRA version: 9.1;Level: PT;Term: Bronchiectasis		Product Name: Cipro Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		122United Kingdom;Germany;Spain;Sweden
2EUCTR2009-009869-34-GB
(EUCTR)		02/09/200909/04/2009Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939 Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)
MedDRA version: 9.1;Level: LLT;Classification code 10006445;Term: Bronchiectasis
MedDRA version: 9.1;Level: PT;Term: Bronchiectasis		Product Name: Cipro Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		122Germany;United Kingdom;Spain;Sweden
3EUCTR2009-009869-34-ES
(EUCTR)		03/07/200906/05/2009 Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis. Estudio aleatorizado, controlado con placebo, en doble ciego y multicéntrico, para evaluar la seguridad y la eficacia de ciprofloxacino inhalado frente a placebo en pacientes con bronquiectasias no debidas a fibrosis quística. Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis. Estudio aleatorizado, controlado con placebo, en doble ciego y multicéntrico, para evaluar la seguridad y la eficacia de ciprofloxacino inhalado frente a placebo en pacientes con bronquiectasias no debidas a fibrosis quística. Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of greater than or equal to 35 % and less than or equal to 80 percent of predicted) Bronquiectasias idiopática y post-neumónica no debidas a fibrosis quística en pacientes en situación pulmonar estable (definida como mayor o igual al 35% y menor o igual al 80%)
MedDRA version: 9.1;Level: LLT;Classification code 10006445;Term: Bronchiectasis
MedDRA version: 9.1;Level: PT;Term: Bronchiectasis 		Bayer HealthCare AGNULLNot Recruiting Female: yes
Male: yes		120Phase 2Spain;Germany;United Kingdom;Sweden
4EUCTR2008-008314-40-DE
(EUCTR)		22/06/200903/03/2009Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosisRandomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis Cystic fibrosis
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin
Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin 		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		276Denmark;Germany;United Kingdom;Sweden
5EUCTR2009-009869-34-DE
(EUCTR)		08/06/200917/03/2009Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939 Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)
MedDRA version: 9.1;Level: LLT;Classification code 10006445;Term: Bronchiectasis
MedDRA version: 9.1;Level: PT;Term: Bronchiectasis		Product Name: Cipro Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		122Spain;Germany;United Kingdom;Sweden
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2008-008314-40-DK
(EUCTR)		02/06/200916/04/2009Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosisRandomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis Cystic fibrosis
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin
Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin 		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		276United Kingdom;Germany;Denmark;Sweden
7NCT00930982
(ClinicalTrials.gov)		June 200930/6/2009Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis BronchiectasisRandomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis BronchiectasisBronchiectasisDrug: Ciprofloxacin (Cipro, BAYQ3939);Drug: PlaceboBayerNovartisCompleted18 YearsN/AAll124Phase 2United States;Australia;Germany;Spain;Sweden;United Kingdom
8EUCTR2008-008314-40-GB
(EUCTR)		18/05/200909/04/2009Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosisRandomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis Cystic fibrosis
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin
Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin 		Bayer Healthcare AGNULLNot RecruitingFemale: yes
Male: yes		276Germany;United Kingdom;Denmark;Sweden
9EUCTR2008-008314-40-SE
(EUCTR)		15/05/200925/03/2009Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosisRandomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis Cystic fibrosis
MedDRA version: 9.1;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung		Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin
Product Name: Ciprofloxacin Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin 		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		276United Kingdom;Germany;Denmark;Sweden

Back to top